S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
MarketBeat Week in Review – 3/27 - 3/31
What To Do With Your Trades Today (Ad)pixel
'War of the states': EV, chip makers lavished with subsidies
Gas prices increase in NJ, around nation amid higher demand
What To Do With Your Trades Today (Ad)pixel
Lanterns and crescents: more retailers court Ramadan buyers
Shipbuilder Austal executives accused of inflating earnings
Did You See These Trend Reversals? (Ad)pixel
No more room for vroom? Paris votes on banishing e-scooters
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
MarketBeat Week in Review – 3/27 - 3/31
What To Do With Your Trades Today (Ad)pixel
'War of the states': EV, chip makers lavished with subsidies
Gas prices increase in NJ, around nation amid higher demand
What To Do With Your Trades Today (Ad)pixel
Lanterns and crescents: more retailers court Ramadan buyers
Shipbuilder Austal executives accused of inflating earnings
Did You See These Trend Reversals? (Ad)pixel
No more room for vroom? Paris votes on banishing e-scooters
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
MarketBeat Week in Review – 3/27 - 3/31
What To Do With Your Trades Today (Ad)pixel
'War of the states': EV, chip makers lavished with subsidies
Gas prices increase in NJ, around nation amid higher demand
What To Do With Your Trades Today (Ad)pixel
Lanterns and crescents: more retailers court Ramadan buyers
Shipbuilder Austal executives accused of inflating earnings
Did You See These Trend Reversals? (Ad)pixel
No more room for vroom? Paris votes on banishing e-scooters
S&P 500   4,109.31
DOW   33,274.15
QQQ   320.93
MarketBeat Week in Review – 3/27 - 3/31
What To Do With Your Trades Today (Ad)pixel
'War of the states': EV, chip makers lavished with subsidies
Gas prices increase in NJ, around nation amid higher demand
What To Do With Your Trades Today (Ad)pixel
Lanterns and crescents: more retailers court Ramadan buyers
Shipbuilder Austal executives accused of inflating earnings
Did You See These Trend Reversals? (Ad)pixel
No more room for vroom? Paris votes on banishing e-scooters
LON:HIK

Hikma Pharmaceuticals - HIK Share Forecast, Price & News

GBX 1,675
-5.50 (-0.33%)
(As of 03/31/2023 12:00 AM ET)
Add
Compare
Today's Range
1,669
▼
1,695
50-Day Range
1,631.43
▼
1,808.50
52-Week Range
1,174.50
▼
2,095.45
Volume
284,841 shs
Average Volume
410,705 shs
Market Capitalization
£3.69 billion
P/E Ratio
2,463.24
Dividend Yield
2.75%
Price Target
GBX 1,882

Hikma Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
12.4% Upside
GBX 1,882 Price Target
Short Interest
N/A
Dividend Strength
Weak
Based on Four Factors
Sustainability
-2.61
Upright™ Environmental Score
News Sentiment
0.12mentions of Hikma Pharmaceuticals in the last 14 days
Based on 9 Articles This Week
Insider Trading
Acquiring Shares
£1.70 M Bought Last Quarter
Proj. Earnings Growth
N/A

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.22 out of 5 stars

See Top Rated MarketRank™ Stocks Here

HIK stock logo

About Hikma Pharmaceuticals (LON:HIK) Stock

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. The company offers its products in solid, semi-solid, liquid, and injectable final dosage forms. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals. The Generics segment offers oral and other non-injectable generic products for the retail market. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The company provides its products in various therapeutic areas, including anti-infective, cardiovascular, central nervous system, diabetes, oncology, pain management, and respiratory. It operates in the United Kingdom, the United States, the Middle East, North Africa, Europe, and internationally. The company was founded in 1978 and is based in London, the United Kingdom.

Receive HIK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Hikma Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

HIK Stock News Headlines

March 31, 2023 | uk.finance.yahoo.com
Naloxone Spray Global Market Report 2023
March 29, 2023 | marketwatch.com
Esmolol Hydrochloride Market Application, Product, Sales and Forecast 2023-2031
April 2, 2023 | Vantage Point (Ad)
Did You See These Trend Reversals?
Get ready for a potentially shocking and unprecedented announcement from the Fed meeting on May 3rd. This could cause many retail and industry traders to resort to drastic measures. One swift stroke could make popular assets plummet, BUT… there’s a straightforward solution to act now to protect your family and wealth. pixel
March 29, 2023 | marketwatch.com
Inhalation & Nasal Sprays Generic Drugs Market by 2031
March 29, 2023 | americanbankingnews.com
Hikma Pharmaceuticals PLC (LON:HIK) Receives GBX 1,882 Consensus Price Target from Analysts
March 28, 2023 | marketwatch.com
Opioid Use Disorder Market Size, Share, Growth, Analysis, Trends and Forecast to 2031
March 28, 2023 | marketwatch.com
Zolpidem Tartrate Market 2023 Size and Forecast to 2030
March 28, 2023 | marketwatch.com
Alprostadil Injection Market Size and Forecast till 2030
April 2, 2023 | Vantage Point (Ad)
Did You See These Trend Reversals?
Get ready for a potentially shocking and unprecedented announcement from the Fed meeting on May 3rd. This could cause many retail and industry traders to resort to drastic measures. One swift stroke could make popular assets plummet, BUT… there’s a straightforward solution to act now to protect your family and wealth. pixel
March 28, 2023 | marketwatch.com
Ranitidine (Zantac) Market Growing Demand and Trends 2023 to 2031
March 27, 2023 | marketwatch.com
Zolpidem Tartrate Market Share and Forecast till 2031
March 24, 2023 | marketwatch.com
Cancer Cachexia Therapeutics Market Size, Share and Forecast 2031
March 21, 2023 | marketwatch.com
Promethazine Hydrochloride Injection Market 2023 Future Trends and Forecast 2029 | Sanofi, Pfizer, Hikma Pharmaceuticals
March 21, 2023 | marketwatch.com
Atropine Sulfate Injection Market Share, Size, Financial Summaries Analysis from 2023 to 2029 | Pfizer, American Regent, Hikma Pharmaceuticals
March 21, 2023 | marketwatch.com
Cyclophosphamide Market Growth and Forecast till 2028
March 21, 2023 | americanbankingnews.com
Hikma Pharmaceuticals PLC (LON:HIK) Increases Dividend to $0.37 Per Share
March 15, 2023 | uk.finance.yahoo.com
$426.3+ Billion Worldwide Generic Pharmaceuticals Industry to 2032: North America was the Largest Region in 2022
March 15, 2023 | marketwatch.com
Global Zolpidem Tartrate Market Size by Type (Sublingual Tablets, Oral Spray) Forecast from 2023 to 2028
March 15, 2023 | marketwatch.com
Azelastine Market Share and Forecast till 2028
March 15, 2023 | marketwatch.com
Total Intravenous Anesthesia (TIVA) Market Significant Growth and Revenue Till 2028
March 14, 2023 | marketwatch.com
Hikma Pharmaceuticals rises Tuesday, still underperforms market
March 14, 2023 | msn.com
Qatar's Health Minister Ranks 3rd Place in Forbes List 2023
March 14, 2023 | msn.com
Forbes Middle East Reveals Top 100 Healthcare Leaders 2023 List
March 14, 2023 | marketwatch.com
Anaesthetic Medicines Market 2023 Expected to Reach Significant Rate by 2028
March 14, 2023 | marketwatch.com
Generic Injectables Market : Regulations, Strategic Industry Growth Analysis, Market Size Between 2023 to 2030
March 13, 2023 | marketwatch.com
Cold Sore Treatment Market Application, Product, Sales and Forecast 2023-2028
March 13, 2023 | msn.com
Forbes Middle East Unveils The Region’s Top 100 Healthcare Leaders
See More Headlines
Receive HIK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Hikma Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

HIK Company Calendar

Ex-Dividend for 5/5 Dividend
3/23/2023
Today
4/01/2023
Dividend Payable
5/05/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
LON
Industry
Drug Manufacturers - Specialty & Generic
Sub-Industry
N/A
Sector
Medical
Current Symbol
LON:HIK
CUSIP
N/A
CIK
N/A
Web
www.hikma.com
Phone
+44-20-73992760
Fax
N/A
Employees
8,700
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
GBX 1,882
High Stock Price Forecast
GBX 2,100
Low Stock Price Forecast
GBX 1,700
Forecasted Upside/Downside
+12.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
6 Analysts

Profitability

EPS (Most Recent Fiscal Year)
GBX 0.68
Trailing P/E Ratio
2,463.24
Forward P/E Ratio
18.13
P/E Growth
2.38
Net Income
£188 million
Net Margins
7.47%
Pretax Margin
N/A
Return on Equity
8.28%
Return on Assets
8.35%

Debt

Debt-to-Equity Ratio
59.73
Current Ratio
1.86
Quick Ratio
1.27

Sales & Book Value

Annual Sales
£2.52 billion
Price / Sales
1.46
Cash Flow
GBX 200.87 per share
Price / Cash Flow
8.34
Book Value
GBX 969 per share
Price / Book
1.73

Miscellaneous

Outstanding Shares
220,260,000
Free Float
N/A
Market Cap
£3.69 billion
Optionable
Not Optionable
Beta
0.31

Key Executives

  • Engineer Said Samih Taleb Darwazah (Age 65)
    Exec. Chairman & CEO
    Comp: $2.71M
  • Mr. Mazen Samih Taleb Darwazah (Age 64)
    Exec. Vice Chairman & Pres of MENA
    Comp: $2.11M
  • Mr. Khalid Waleed Hosny Al Nabilsi (Age 50)
    Chief Financial Officer
  • Mr. Hussein Arkhagha
    Company Sec. & Chief Counsel
  • Mr. Bassam Wael Rushdi Kanaan CFA (Age 57)
    CPA, Exec. VP of Corp. Devel. and M&A
  • Ms. Susan Ringdal
    Exec. VP of Strategic Planning & Global Affairs
  • Ms. Majda Labadi
    Exec. VP of Organisational Devel.
  • Mr. Riad Mishlawi
    Pres of Injectables
  • Mr. Brian Hoffmann
    Pres of Generics
  • Mr. Samuel Park
    Global Head of Intellectual Property (IP) & Gen. Counsel for US

Key Competitors

View All Competitors

Insiders

View All Insider Transactions













HIK Stock - Frequently Asked Questions

Should I buy or sell Hikma Pharmaceuticals stock right now?

6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Hikma Pharmaceuticals in the last twelve months. There are currently 3 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" HIK shares.
View HIK analyst ratings or view top-rated stocks.

What is Hikma Pharmaceuticals' stock price forecast for 2023?

6 equities research analysts have issued 12 month target prices for Hikma Pharmaceuticals' shares. Their HIK share price forecasts range from GBX 1,700 to GBX 2,100. On average, they anticipate the company's stock price to reach GBX 1,882 in the next year. This suggests a possible upside of 12.4% from the stock's current price.
View analysts price targets for HIK or view top-rated stocks among Wall Street analysts.

How have HIK shares performed in 2023?

Hikma Pharmaceuticals' stock was trading at GBX 1,552 on January 1st, 2023. Since then, HIK stock has increased by 7.9% and is now trading at GBX 1,675.
View the best growth stocks for 2023 here.

How often does Hikma Pharmaceuticals pay dividends? What is the dividend yield for Hikma Pharmaceuticals?

Hikma Pharmaceuticals announced a dividend on Thursday, February 23rd. Stockholders of record on Thursday, March 23rd will be given a dividend of GBX 0.37 per share on Friday, May 5th. This represents a dividend yield of 1.74%. The ex-dividend date of this dividend is Thursday, March 23rd. This is an increase from the stock's previous dividend of GBX 0.19. The official announcement can be seen at this link.
Read our dividend analysis for HIK.

Is Hikma Pharmaceuticals a good dividend stock?

Hikma Pharmaceuticals (LON:HIK) pays an annual dividend of GBX 46 per share and currently has a dividend yield of 2.76%. The dividend payout ratio is 6,764.71%. Payout ratios above 75% are not desirable because they may not be sustainable.
Read our dividend analysis for HIK.

What other stocks do shareholders of Hikma Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Hikma Pharmaceuticals investors own include CA (CA), Endologix (ELGX), BlackRock (BLK), Hawkins (HWKN), Chipotle Mexican Grill (CMG), Aegean Marine Petroleum Network (ANW), Athabasca Oil (ATH), Gran Tierra Energy (GTE), Och-Ziff Capital Management Group (OZM) and Belden (BDC).

What is Hikma Pharmaceuticals' stock symbol?

Hikma Pharmaceuticals trades on the London Stock Exchange (LON) under the ticker symbol "HIK."

How do I buy shares of Hikma Pharmaceuticals?

Shares of HIK stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What is Hikma Pharmaceuticals' stock price today?

One share of HIK stock can currently be purchased for approximately GBX 1,675.

How much money does Hikma Pharmaceuticals make?

Hikma Pharmaceuticals (LON:HIK) has a market capitalization of £3.69 billion and generates £2.52 billion in revenue each year. The company earns £188 million in net income (profit) each year or GBX 0.68 on an earnings per share basis.

How many employees does Hikma Pharmaceuticals have?

The company employs 8,700 workers across the globe.

How can I contact Hikma Pharmaceuticals?

Hikma Pharmaceuticals' mailing address is 1 New Burlington Place, LONDON, W1S 2HR, United Kingdom. The official website for the company is www.hikma.com. The company can be reached via phone at +44-20-73992760.

This page (LON:HIK) was last updated on 4/2/2023 by MarketBeat.com Staff